About Bristol Myers Squibb
Bristol Myers Squibb (BMS) is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases. BMS is a leader in oncology, immunology, cardiovascular, and fibrosis treatments.
Oncology Leadership
BMS pioneered immuno-oncology with Opdivo (nivolumab) and Yervoy (ipilimumab), which have transformed cancer treatment for multiple tumor types. The company also offers targeted therapies for lung cancer, multiple myeloma, and blood cancers.
Key Therapeutic Areas
Beyond oncology, BMS has a strong cardiovascular portfolio including Eliquis (apixaban), one of the world's top-selling blood thinners. The immunology franchise includes Orencia and Zeposia, while the fibrosis portfolio focuses on advanced therapies.
Research Pipeline
BMS invests over $9 billion annually in R&D, with a pipeline spanning cell therapies (CAR-T), protein degraders, antibody-drug conjugates, and gene therapies. The company has one of the industry's most promising early-stage pipelines.
Global Presence
Headquartered in New York City, BMS employs 34,000+ people worldwide, operating in more than 60 countries. The company reported $45 billion in revenue in 2023, driven by its oncology and cardiovascular franchises.
Leadership
Christopher Boerner became CEO in 2023, succeeding Giovanni Caforio. The company was formed through the landmark merger of Bristol-Myers Squibb and Celgene in 2019.